(Q33258089)

24 July 2017

1 reference

title

Cilomilast: orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

24 July 2017

main subject

1 reference

Shaunta' D Martina

1

1 reference

24 July 2017

Maha S Ismail

series ordinal

2

1 reference

24 July 2017

Kimi S Vesta

series ordinal

3

1 reference

24 July 2017

language of work or name

English

0 references

publication date

19 September 2006

1 reference

Annals of Pharmacotherapy

24 July 2017

published in

1 reference

24 July 2017

volume

40

1 reference

24 July 2017

issue

10

1 reference

24 July 2017

page(s)

1822-1828

1 reference

Delays in managing lung cancer

24 July 2017

cites work

1 reference

Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic

21 January 2018

1 reference

Phosphodiesterase 4 inhibitors for the treatment of COPD.

21 January 2018

1 reference

Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells.

21 January 2018

1 reference

Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD.

21 January 2018

1 reference

Bioavailability of the oral selective phosphodiesterase 4 inhibitor cilomilast

21 January 2018

1 reference

An overview of the pharmacokinetics of cilomilast (Ariflo), a new, orally active phosphodiesterase 4 inhibitor, in healthy young and elderly volunteers

21 January 2018

1 reference

Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4.

21 January 2018

1 reference

Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study

21 January 2018

1 reference

Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in patients with chronic obstructive pulmonary disease?

21 January 2018

1 reference

Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease

21 January 2018

1 reference

Cilomilast (Ariflo) does not potentiate the cardiovascular effects of inhaled salbutamol

21 January 2018

1 reference

Lack of pharmacokinetic interactions between cilomilast and theophylline or smoking in healthy volunteers

21 January 2018

1 reference

Warfarin pharmacodynamics unaffected by cilomilast

21 January 2018

1 reference

Cilomilast: pharmacokinetic and pharmacodynamic interactions with digoxin

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1H049

1 reference

24 July 2017

1 reference